LISCURE BIOSCIENCES

liscure-biosciences-logo

LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.

#SimilarOrganizations #People #Financial #Website #More

LISCURE BIOSCIENCES

Industry:
Biotechnology Health Care

Founded:
2018-12-01

Address:
Seoul, Seoul-t'ukpyolsi, South Korea

Country:
South Korea

Website Url:
http://www.liscure.bio

Total Employee:
1+

Status:
Active

Contact:
02-3443-1800

Email Addresses:
admin@liscure.bio

Total Funding:
5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apache Mobile Non Scaleable Content Google Apps For Business Cloudflare JS CDN JS AJAX Libraries API


Similar Organizations

aura-biosciences-logo

Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

innovative-cellular-therapeutics-logo

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.

Current Employees Featured

not_available_image

Hwaseop Chin
Hwaseop Chin Co-Founder & Chief Executive Officer @ LISCure Biosciences
Co-Founder & Chief Executive Officer
2018-12-01

not_available_image

Junyoung Kil
Junyoung Kil Chief Financial Officer @ LISCure Biosciences
Chief Financial Officer
2018-12-01

Founder


not_available_image

Hwaseop Chin

not_available_image

Junyoung Kil

Investors List

kb-securities_image

KB Securities

KB Securities investment in Seed Round - LISCure Biosciences

shinhan-investment-corporation_image

Shinhan Investment

Shinhan Investment investment in Seed Round - LISCure Biosciences

nhn-investment_image

NHN Investment

NHN Investment investment in Seed Round - LISCure Biosciences

Official Site Inspections

http://www.liscure.bio Semrush global rank: 4.34 M Semrush visits lastest month: 986

  • Host name: 183.111.169.45
  • IP address: 183.111.169.45
  • Location: South Korea
  • Latitude: 37.5112
  • Longitude: 126.9741
  • Timezone: Asia/Seoul

Cannot get whois informations of this domain!!!

More informations about "LISCure Biosciences"

LISCure

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancerimmunotherapy” and “oral microbiome therapeutics.” The LMT (LISCure …See details»

LISCure Biosciences - Crunchbase Company Profile

LISCure Biosciences is a biotech company that researches and develops bacteria-mediated immunotherapy. View contacts for LISCure Biosciences to access new leads and connect with decision-makers.See details»

LISCure

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”See details»

LISCure

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.” LISCure is developing …See details»

LISCure Biosciences Company Profile 2024: Valuation, …

Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer.See details»

LISCure Biosciences Inc. - LinkedIn

LISCure is a clinical-stage biotherapeutic company focused on developing bacteria-mediated immunotherapy using a single strain approach for major therapeutic areas. The company focuses on...See details»

LISCure Biosciences Announces FDA Clearance of IND Application …

Feb 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»

LISCure Biosciences receives U.S. FDA Fast Track designation for …

Mar 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs and drug delivery platforms based on innovative modalities for the areas with high …See details»

LISCure Biosciences Announces FDA Clearance of IND Application …

Feb 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»

LISCure

Mar 4, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»

LISCure's Phase 2 Drug Candidate Granted Orphan Drug …

SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), …See details»

Celltrion and LISCure Biosciences announce strategic collaboration …

SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ — LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a …See details»

LISCure, the first Korean biotech company receiving equity …

Jul 26, 2021 · LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to …See details»

LISCure Biosciences receives U.S. FDA Fast Track designation for …

Mar 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs and drug delivery platforms based on innovative modalities for the areas with high …See details»

LISCure Biosciences announces research collaboration with Mayo …

Jan 6, 2022 · LISCure has been conducting joint research with Mayo Clinic for NASH drugs since 2021, and this new collaboration is an agreement signed under the leadership of Nicholas F. …See details»

LISCure

We plan to develop personalized therapeutics by analyzing the gut microbiome, individual immunity, and metabolite profiles using this platform.See details»

LISCure Biosciences Announces Oral Presentation of New Drug …

SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative …See details»

LISCure Biosciences Announces FDA Clearance of IND Application …

Feb 29, 2024 · LISCure has its own screening platform technology based on a proprietary in-house microorganism bank and is dedicated to developing first-in-class new drugs against …See details»

LISCure Bioscience Co. Ltd. (LISCure Bioscience Co. Ltd.) - 药物管 …

The US Food and Drug Administration (FDA) has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of primary sclerosing cholangitis …See details»

LISCure

Dec 9, 2022 · LISCure, through research collaboration with Mayo Clinic, has demonstrated therapeutic efficacy in PSC in animal models. Global Pharmaceutical companies have been …See details»

linkstock.net © 2022. All rights reserved